Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL)

被引：1
|
作者：
Carlo-Stella, C.
Guidetti, A.
Viviani, S.
Bonfante, V.
Marchiano, A.
Gatti, B.
D'Urzo, C.
Di Nicola, M. A.
Corradini, P.
Gianni, A. M.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Italfarmaco SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3068
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL).
    Carlo-Stella, Carmelo
    Guidetti, Anna
    Viviani, Simonetta
    Bonfante, Valeria
    Valagussa, Pinuccia
    Marchiano, Alfonso
    Crippa, Flavio
    Zambelli, Stefania
    Fasola, Cinzia
    Corradini, Paolo
    Tarella, Corrado
    Di Nicola, Massimo
    Gianni, Alessandro M.
    BLOOD, 2008, 112 (11) : 896 - 897
  • [2] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Younes, A.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Bociek, R. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [3] A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Kopko, Anne
    Fehniger, Todd A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    BLOOD, 2012, 120 (21)
  • [4] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
    Bociek, R. G.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
    Christian, Beth
    Wei, Lai
    Sexton, Jennifer
    Jaglowski, Samantha M.
    Devine, Steven M.
    Fehniger, Todd A.
    Wagner-Johnston, Nina
    Bartlett, Nancy L.
    Blum, Kristie A.
    BLOOD, 2014, 124 (21)
  • [6] Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACI), demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL)
    Spencer, A.
    DeAngelo, D. J.
    Prince, H. M.
    Bhalla, K. N.
    Fischer, T.
    Liu, A.
    Parker, K.
    Jalaluddin, M.
    Scott, J. W.
    Ottmann, O. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [7] A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
    Batlevi, Connie L.
    Crump, Michael
    Andreadis, Charalambos
    Rizzieri, David
    Assouline, Sarit E.
    Fox, Susan
    van der Jagt, Richard H. C.
    Copeland, Amanda
    Potvin, Diane
    Chao, Richard
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (03) : 434 - 441
  • [8] Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
    Younes, Anas
    Bociek, R. Gregory
    Kuruvilla, John
    Laneuville, Pierre
    Fung, Henry C.
    Drouin, Michel
    Patterson, Tracy
    Besterman, Jeffrey
    Martell, Robert E.
    BLOOD, 2010, 116 (21) : 735 - 735
  • [9] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    BLOOD, 2010, 116 (21) : 1159 - 1159
12345